Prenylation of HDAg and Antiviral Drug Development

2006 ◽  
pp. 133-149 ◽  
Author(s):  
J. S. Glenn
Keyword(s):  
Drug Development ◽  
Antiviral Drug

scholarly journals Native Structure-Based Peptides as Potential Protein–Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor

Molecules ◽  
2021 ◽  
Vol 26 (8) ◽  
pp. 2157
Author(s):  
Norbert Odolczyk ◽  
Ewa Marzec ◽  
Maria Winiewska-Szajewska ◽  
Jarosław Poznański ◽  
Piotr Zielenkiewicz
Keyword(s):  
Drug Development ◽  
Protein Interactions ◽  
Rna Virus ◽  
Antiviral Drug ◽  
Host Protein ◽  
Host Cells ◽  
Cell Surface Receptor ◽  
Short Peptides ◽  
Virus Protein ◽  
Positive Strand Rna

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a positive-strand RNA virus that causes severe respiratory syndrome in humans, which is now referred to as coronavirus disease 2019 (COVID-19). Since December 2019, the new pathogen has rapidly spread globally, with over 65 million cases reported to the beginning of December 2020, including over 1.5 million deaths. Unfortunately, currently, there is no specific and effective treatment for COVID-19. As SARS-CoV-2 relies on its spike proteins (S) to bind to a host cell-surface receptor angiotensin-converting enzyme-2(ACE2), and this interaction is proved to be responsible for entering a virus into host cells, it makes an ideal target for antiviral drug development. In this work, we design three very short peptides based on the ACE2 sequence/structure fragments, which may effectively bind to the receptor-binding domain (RBD) of S protein and may, in turn, disrupt the important virus-host protein–protein interactions, blocking early steps of SARS-CoV-2 infection. Two of our peptides bind to virus protein with affinity in nanomolar range, and as very short peptides have great potential for drug development.

scholarly journals Using mutagenesis to explore conserved residues in the RNA-binding groove of influenza A virus nucleoprotein for antiviral drug development

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Chia-Lin Liu ◽  
Hui-Chen Hung ◽  
Shou-Chen Lo ◽  
Ching-Hui Chiang ◽  
I-Jung Chen ◽  
...  
Keyword(s):  
Drug Development ◽  
Influenza A Virus ◽  
Influenza A ◽  
Rna Binding ◽  
Antiviral Drug ◽  
Conserved Residues ◽  
Binding Groove

Antiviral drug development: progress and pitfalls

2008 ◽  
Vol 3 (6) ◽  
pp. 529-532
Author(s):  
Dimitrios Coutsinos ◽  
Richard Sloan ◽  
Mark A Wainberg
Keyword(s):  
Drug Development ◽  
Antiviral Drug

The 4′,4′-difluoro analog of 5′-noraristeromycin: A new structural prototype for possible antiviral drug development toward orthopoxvirus and cytomegalovirus

2005 ◽  
Vol 13 (14) ◽  
pp. 4443-4449 ◽  
Author(s):  
Atanu Roy ◽  
Stewart W. Schneller ◽  
Kathy A. Keith ◽  
Caroll B. Hartline ◽  
Earl R. Kern
Keyword(s):  
Drug Development ◽  
Antiviral Drug

scholarly journals The flavivirus NS2B–NS3 protease–helicase as a target for antiviral drug development

2015 ◽  
Vol 118 ◽  
pp. 148-158 ◽  
Author(s):  
Dahai Luo ◽  
Subhash G. Vasudevan ◽  
Julien Lescar
Keyword(s):  
Drug Development ◽  
Antiviral Drug ◽  
Ns3 Protease
Sign in / Sign up

Export Citation Format

Share Document